GILD SEC Filing News — Gilead Sciences, Inc.

Latest SEC filings for Gilead Sciences, Inc. (GILD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for…
Sector: Healthcare Industry: Drug Manufacturers - General Market Cap: $179.3B CIK: 882095
20
Total Filings
0
Bullish Classifications
8
Bearish Classifications
14
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for GILD currently lean bearish. Of the 20 filing records displayed, 8 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
GILD Filing Activity Snapshot 2026-08-17 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 8 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$3.85M
Mercier Johanna (Chief Comm & Corp Aff Officer) · 2026-08-18
28,000 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for Gilead Sciences, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 8 open-market sale and 6 option exercise. 8 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×8
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×6
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Open-market sale Insider Selling 2026-10-02

GILD insider O'Day Daniel Patrick (Director, Chairman & CEO) sold 15,000 shares (~$2.22M)

O'Day Daniel Patrick, listed as Director, Chairman & CEO at GILEAD SCIENCES, INC., reported an open-market sale of 15,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 12,000 $147.72 $1.77M
S Open-market sale 3,000 $148.63 $445.9K
Filing: Form 4 (Insider Transaction) Insider: O'Day Daniel Patrick (Director, Chairman & CEO) Shares: 15,000 Est. Value: $2.22M
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-23

GILD insider Form 4 filed for equity award, exercise, or tax withholding

Burkhart Erin (SVP, Controllership) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,223 — —
F Tax withholding on vested shares 768 $152.67 $117.3K
M Option exercise derivative · Restricted Stock Unit 2,223 — —
Filing: Form 4 (Insider Transaction) Insider: Burkhart Erin (SVP, Controllership) Shares: 2,991
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-16

GILD insider Dickinson Andrew D (Chief Financial Officer) sold 3,000 shares (~$435.9K)

Dickinson Andrew D, listed as Chief Financial Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,000 $145.29 $435.9K
Filing: Form 4 (Insider Transaction) Insider: Dickinson Andrew D (Chief Financial Officer) Shares: 3,000 Est. Value: $435.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-16

GILD insider Mercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares (~$432.6K)

Mercier Johanna, listed as Chief Comm & Corp Aff Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,600 $143.69 $229.9K
S Open-market sale 800 $144.46 $115.6K
S Open-market sale 600 $145.29 $87.2K
Filing: Form 4 (Insider Transaction) Insider: Mercier Johanna (Chief Comm & Corp Aff Officer) Shares: 3,000 Est. Value: $432.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

GILD insider Form 4 filed for equity award, exercise, or tax withholding

Dickinson Andrew D (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,797 — —
F Tax withholding on vested shares 1,347 $144.81 $195.1K
M Option exercise derivative · Restricted Stock Unit 2,797 — —
Filing: Form 4 (Insider Transaction) Insider: Dickinson Andrew D (Chief Financial Officer) Shares: 4,144
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

GILD insider Form 4 filed for equity award, exercise, or tax withholding

Berger Dietmar (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 533 — —
F Tax withholding on vested shares 263 $144.81 $38.1K
M Option exercise derivative · Restricted Stock Unit 533 — —
Filing: Form 4 (Insider Transaction) Insider: Berger Dietmar (Chief Medical Officer) Shares: 796
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

GILD insider Form 4 filed for equity award, exercise, or tax withholding

Mercier Johanna (Chief Comm & Corp Aff Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,797 — —
F Tax withholding on vested shares 1,347 $144.81 $195.1K
M Option exercise derivative · Restricted Stock Unit 2,797 — —
Filing: Form 4 (Insider Transaction) Insider: Mercier Johanna (Chief Comm & Corp Aff Officer) Shares: 4,144
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

GILD insider Form 4 filed for equity award, exercise, or tax withholding

Cain Wettan Keeley M (EVP Gen Counsel, Legal & Comp) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 590 — —
F Tax withholding on vested shares 285 $144.81 $41.3K
M Option exercise derivative · Restricted Stock Unit 590 — —
Filing: Form 4 (Insider Transaction) Insider: Cain Wettan Keeley M (EVP Gen Counsel, Legal & Comp) Shares: 875
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-11

GILD insider Form 4 filed for equity award, exercise, or tax withholding

O'Day Daniel Patrick (Director, Chairman & CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 8,780 — —
F Tax withholding on vested shares 4,230 $144.81 $612.5K
M Option exercise derivative · Restricted Stock Unit 8,780 — —
Filing: Form 4 (Insider Transaction) Insider: O'Day Daniel Patrick (Director, Chairman & CEO) Shares: 13,010
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-02

GILD insider O'Day Daniel Patrick (Director, Chairman & CEO) sold 15,000 shares (~$2.23M)

O'Day Daniel Patrick, listed as Director, Chairman & CEO at GILEAD SCIENCES, INC., reported an open-market sale of 15,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,600 $147.51 $236.0K
S Open-market sale 7,992 $148.36 $1.19M
S Open-market sale 5,408 $149.38 $807.9K
Filing: Form 4 (Insider Transaction) Insider: O'Day Daniel Patrick (Director, Chairman & CEO) Shares: 15,000 Est. Value: $2.23M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-27

GILD insider WELTERS ANTHONY (Director) sold 18,000 shares (~$2.68M)

WELTERS ANTHONY, listed as Director at GILEAD SCIENCES, INC., reported an open-market sale of 18,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 7,718 $60.67 $468.3K
S Open-market sale 3,118 $148.31 $462.4K
S Open-market sale 4,600 $148.82 $684.6K
M Option exercise 10,282 $61.35 $630.8K
S Open-market sale 3,402 $148.24 $504.3K
S Open-market sale 6,880 $148.82 $1.02M
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 7,718 — —
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 10,282 — —
Filing: Form 4 (Insider Transaction) Insider: WELTERS ANTHONY (Director) Shares: 18,000 Est. Value: $2.68M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-21

GILD insider Bluestone Jeffrey (Director) sold 5,000 shares (~$725.1K)

Bluestone Jeffrey, listed as Director at GILEAD SCIENCES, INC., reported an open-market sale of 5,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,165 $67.45 $78.6K
S Open-market sale 1,165 $143.75 $167.5K
M Option exercise 1,816 $67.45 $122.5K
S Open-market sale 1,816 $144.92 $263.2K
M Option exercise 1,658 $67.45 $111.8K
S Open-market sale 1,658 $145.73 $241.6K
M Option exercise 26 $67.45 $1.8K
S Open-market sale 26 $146.36 $3.8K
M Option exercise 335 $61.35 $20.6K
S Open-market sale 335 $146.26 $49.0K
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 4,665 — —
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 335 — —
Filing: Form 4 (Insider Transaction) Insider: Bluestone Jeffrey (Director) Shares: 5,000 Est. Value: $725.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-18

GILD insider Dickinson Andrew D (Chief Financial Officer) sold 3,000 shares (~$415.1K)

Dickinson Andrew D, listed as Chief Financial Officer at GILEAD SCIENCES, INC., reported an open-market sale of 3,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,000 $138.36 $415.1K
Filing: Form 4 (Insider Transaction) Insider: Dickinson Andrew D (Chief Financial Officer) Shares: 3,000 Est. Value: $415.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-18

GILD insider Mercier Johanna (Chief Comm & Corp Aff Officer) sold 28,000 shares (~$3.85M)

Mercier Johanna, listed as Chief Comm & Corp Aff Officer at GILEAD SCIENCES, INC., reported an open-market sale of 28,000 GILD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 23,110 $66.64 $1.54M
M Option exercise 1,890 $72.34 $136.7K
S Open-market sale 16,530 $137.37 $2.27M
S Open-market sale 11,470 $138.04 $1.58M
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 23,110 — —
M Option exercise derivative · Non-qualified Stock Option (Right to Buy) 1,890 — —
Filing: Form 4 (Insider Transaction) Insider: Mercier Johanna (Chief Comm & Corp Aff Officer) Shares: 28,000 Est. Value: $3.85M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Gilead Sciences, Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-15

GILD Form 144 filed for proposed insider sale by JOHANNA MERCIER (3,000 shares) ~$432.6K

JOHANNA MERCIER filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOHANNA MERCIER Shares: 3,000 Est. Value: $432.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-15

GILD Form 144 filed for proposed insider sale by ANDREW DICKINSON (3,000 shares) ~$435.9K

ANDREW DICKINSON filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ANDREW DICKINSON Shares: 3,000 Est. Value: $435.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-26

GILD Form 144 filed for proposed insider sale by ANTHONY WELTERS (18,000 shares) ~$2.68M

ANTHONY WELTERS filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ANTHONY WELTERS Shares: 18,000 Est. Value: $2.68M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-20

GILD Form 144 filed for proposed insider sale by JEFFREY BLUESTONE (5,000 shares) ~$738.0K

JEFFREY BLUESTONE filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JEFFREY BLUESTONE Shares: 5,000 Est. Value: $738.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-17

GILD Form 144 filed for proposed insider sale by JOHANNA MERCIER (28,000 shares) ~$3.85M

JOHANNA MERCIER filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOHANNA MERCIER Shares: 28,000 Est. Value: $3.85M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-17

GILD Form 144 filed for proposed insider sale by ANDREW DICKINSON (3,000 shares) ~$415.1K

ANDREW DICKINSON filed a Form 144 with the SEC indicating intent to sell GILD (GILEAD SCIENCES, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ANDREW DICKINSON Shares: 3,000 Est. Value: $415.1K
View on SEC EDGAR → Open Filing Document →

How we classify Gilead Sciences, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on GILD. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — GILD SEC Filings

What SEC filings does Gilead Sciences, Inc. submit to the SEC?

Gilead Sciences, Inc. (GILD) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about GILD?

A Form 4 for GILD discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Gilead Sciences, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for GILD?

The 10-K is Gilead Sciences, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all GILD SEC filings directly on EDGAR?

You can view all historical Gilead Sciences, Inc. filings on the SEC EDGAR company page for GILD. Each filing card on this page links directly to the original SEC document.

How often does Gilead Sciences, Inc. file with the SEC?

Gilead Sciences, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling GILD shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for GILD

GILD Full Stock Analysis GILD Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper GILD analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the GILD stock analysis page.

GILD Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer